Literature DB >> 3341822

Suppressive effect of ulinastatin on plasma fibronectin depression after cardiac surgery.

M Haniuda1, M Morimoto, A Sugenoya, F Iida.   

Abstract

Plasma fibronectin, an opsonic glycoprotein, is known to modulate the reticuloendothelial phagocytic clearance of nonbacterial and, possibly, bacterial particulates. The decreased plasma fibronectin levels seen after cardiac surgery have been considered to derive mainly from opsonic consumption. In the present study, we demonstrated that the administration of ulinastatin, a human urinary trypsin inhibitor, to patients after cardiac surgery not only inhibited the postoperative depression of plasma fibronectin levels, but also maintained the plasma fibronectin level within the normal range. This effect apparently resulted from the inhibitory activity of ulinastatin on the proteolytic enzymes released after operation. This result suggests that the decreased plasma fibronectin level noted after cardiac surgery may derive mostly from excessive proteolytic enzymes. Our observation also indicates that the prophylactic administration of ulinastatin to patients undergoing major operations will result in a favorably functional reticuloendothelial phagocytic system.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3341822     DOI: 10.1016/s0003-4975(10)62431-9

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  2 in total

1.  Severe thoracic trauma caused left pneumonectomy complicated by right traumatic wet lung, reversed by extracorporeal membrane oxygenation support-a case report.

Authors:  Feng Yun Wang; Bin Fang; Zhi Hui Yu; Jing Song Shao; Wei Biao Wen; Li Xin Zhou
Journal:  BMC Pulm Med       Date:  2019-02-06       Impact factor: 3.317

Review 2.  The Efficacy and Immunomodulatory Effects of Ulinastatin and Thymosin α1 for Sepsis: A Systematic Review and Meta-Analysis.

Authors:  Feng Yun Wang; Bin Fang; Xin Hua Qiang; Tie Ou Yu; Jia Rong Zhong; Jun Cao; Li Xin Zhou
Journal:  Biomed Res Int       Date:  2016-05-31       Impact factor: 3.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.